Tamoxifen citrate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100800

CAS#: 54965-24-1

Description: Tamoxifen, also known as ICI 46474, is an antagonist of the estrogen receptor in breast tissue via its active metabolite, 4-hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a selective estrogen-receptor modulator. Tamoxifen is the usual endocrine (anti-estrogen) therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting.


Price and Availability

Size
Price

1g
USD 150
10g
USD 750
100g
Ask price
Size
Price

2g
USD 250
25g
USD 1450
Size
Price

5g
USD 450
50g
USD 2650

Tamoxifen citrate, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide).


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 100800
Name: Tamoxifen citrate
CAS#: 54965-24-1
Chemical Formula: C32H37NO8
Exact Mass:
Molecular Weight: 563.65
Elemental Analysis: C, 68.19; H, 6.62; N, 2.49; O, 22.71


Related CAS #: 54965-24-1 (citrate)   10540-29-1 (free base)  

Synonym: ICI 46474, ICI-46474, ICI46474, NSC 180973, tamoxifen, tamoxifeni citras, Nolvadex, Novaldex

IUPAC/Chemical Name: (Z)-2-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate

InChi Key: FQZYTYWMLGAPFJ-OQKDUQJOSA-N

InChi Code: InChI=1S/C26H29NO.C6H8O7/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,4,19-20H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;

SMILES Code: CC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCN(C)C)C=C2)\C3=CC=CC=C3.O=C(CC(C(O)=O)(O)CC(O)=O)O


Technical Data

Appearance:
White to off-white crystalline powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

 1: Shaikh IA, Brown I, Wahle KW, Heys SD. Enhancing cytotoxic therapies for breast and prostate cancers with polyunsaturated fatty acids. Nutr Cancer. 2010 Apr;62(3):284-96. Review. PubMed PMID: 20358465.

2: Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry. 2009 Dec;70(12):1688-97. Review. PubMed PMID: 20141708.

3: Wills SM, Zekman R, Bestul D, Kuwajerwala N, Decker D. Tamoxifen malabsorption after Roux-en-Y gastric bypass surgery: case series and review of the literature. Pharmacotherapy. 2010 Feb;30(2):217. Review. PubMed PMID: 20099995.

4: Rodriguez-Antona C, Gomez A, Karlgren M, Sim SC, Ingelman-Sundberg M. Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. Hum Genet. 2010 Jan;127(1):1-17. Epub 2009 Oct 8. Review. PubMed PMID: 19823875.

5: Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin. 2009 Jan-Feb;59(1):42-55. Review. PubMed PMID: 19147868.

6: Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 2009 Jan 31;61(1):26-33. Epub 2008 Dec 3. Review. PubMed PMID: 19111841.

7: Petrakova K, Růzicková J, Fait V. [Therapeutic approaches for breast carcinoma]. Klin Onkol. 2008;21(4):131-40. Review. Czech. PubMed PMID: 19102218.

8: Sengupta S, Jordan VC. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Adv Exp Med Biol. 2008;630:206-19. Review. PubMed PMID: 18637493.

9: Saynak M, Cosar-Alas R, Yurut-Caloglu V, Caloglu M, Kocak Z, Uzal C. Chemotherapy and cerebrovascular disease. J BUON. 2008 Jan-Mar;13(1):31-6. Review. PubMed PMID: 18404783.

10: Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. Drug Saf. 2008;31(2):127-41. Review. PubMed PMID: 18217789.